✦ LIBER ✦

Denosumab a boon for bone mineral density in prostate cancer

Book ID: 120843438
Publisher: Adis International Limited (now part of Wolters Kluwer Health)
Year: 2008
Weight: 138 KB
Volume: &NA;
Category: Article
ISSN: 1173-8324
DOI: 10.2165/00128413-200816470-00015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Denosumab in Postmenopausal Women with L

Denosumab in Postmenopausal Women with Low Bone Mineral Density

✍ McClung, Michael R.; Lewiecki, E. Michael; Cohen, Stanley B.; Bolognese, Michael 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 296 KB

Lumbar Bone Mineral Density in Prostate

Lumbar Bone Mineral Density in Prostate Cancer Patients with Bone Metastases

✍ Chang, Chao‐Hsiang; Tsai, Chang‐Shu; Jim, Yick‐Fung; Wu, Hsi‐Chin; Lin, Cheng‐Ch 📂 Article 📅 2003 🏛 Informa plc 🌐 English ⚖ 139 KB

EFFECTS OF TWICE-YEARLY SUBCUTANEOUS DEN

EFFECTS OF TWICE-YEARLY SUBCUTANEOUS DENOSUMAB ON BONE MINERAL DENSITY IN MEN RECEIVING ANDROGEN-DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER

✍ Smith, Matthew R; Egerdie, Blair; Szwedowski, Maciej; Ke, Chunlei; Leder, Ben; G 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 49 KB

A RESPONDER ANALYSIS OF THE EFFECTS OF D

A RESPONDER ANALYSIS OF THE EFFECTS OF DENOSUMAB ON BONE MINERAL DENSITY IN MEN WITH PROSTATE CANCER RECEIVING ANDROGEN DEPRIVATION THERAPY

✍ Egerdie, Blair; Smith, Matthew R; Tammela, Teuvo L j; Saad, Fred; Ke, Chunlei; G 📂 Article 📅 2009 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 69 KB

Effects of Denosumab on Bone Mineral Den

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

✍ Bone, Henry G.; Bolognese, Michael A.; Yuen, Chui Kin; Kendler, David L.; Wang, 📂 Article 📅 2008 🏛 Endocrine Society 🌐 English ⚖ 169 KB

Denosumab and changes in bone turnover m

Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer

✍ Matthew R Smith; Fred Saad; Blair Egerdie; Paul Sieber; Teuvo LJ Tammela; Benjam 📂 Article 📅 2011 🏛 American Society for Bone and Mineral Research 🌐 English ⚖ 127 KB

## Abstract Androgen deprivation therapy (ADT) for prostate cancer increases fracture risk, decreases bone mineral density, and increases bone turnover markers (BTMs) including serum type 1 C‐telopeptide (sCTX), tartrate‐resistant alkaline phosphatase 5b (TRAP‐5b), and procollagen‐1 N‐terminal telo